RNA sequencing and whole genome sequencing services

The National Institutes of Health (NIH) National Cancer Institute intends to award a sole‑source, firm‑fixed‑price order to Plasmidsaurus Inc. for RNA sequencing and whole‑genome sequencing services supporting CRISPR‑based lymphoma research. The work will involve sequencing wild‑type and drug‑treated cell lines to characterize genomic edits, identify translocations (MYC, BCL6, BCL2), and generate copy‑number variation data for downstream analysis. The award will be made shortly after the submission deadline, with the expectation that the selected vendor will deliver sequencing data using Oxford Nanopore Technologies platforms. • Provide RNA‑seq and WGS services for multiple cell‑line samples. • Use latest Oxford Nanopore platform to produce high‑throughput, scalable sequencing results. • Deliver data supporting investigation of lymphoma‑related genetic alterations and drug response pathways.